Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us

Download Mobile App




Blood Test Detects Multiple Sclerosis Risk Years Before Onset of Symptoms

By LabMedica International staff writers
Posted on 16 Jul 2025

Multiple sclerosis (MS) is a chronic inflammatory disease of the central nervous system that affects around 2. More...

8 million people worldwide. Its development is linked to immunological processes triggered by Epstein-Barr virus (EBV) infection. Though the virus is widespread, present in 90-95% of the population, MS remains difficult to diagnose early due to the lack of clear symptoms in its early stages. MS typically manifests years after the initial EBV infection, making it challenging to predict and treat the disease before symptoms appear. Current diagnostic methods, such as neurofilament light chain (NfL) or glial fibrillary acidic protein (GFAP) levels, only detect nerve cell damage later in the disease process. Now, a new blood test enables accurate identification of individuals at risk for developing MS years before the onset of symptoms.

The blood test developed by researchers at the Medical University of Vienna (Vienna, Austria) detects autoantibodies that react to both the EBV protein EBNA-1 and structures in the human brain. These antibodies can be detected within three years of an EBV infection, long before clinical symptoms of MS appear. The test identifies individuals at higher risk for MS by repeatedly measuring the levels of these antibodies. The test could be used to track individuals who are at a higher risk of developing MS in the coming years. This breakthrough could enable early intervention, potentially delaying or even preventing the onset of MS.

The test was validated through a retrospective study involving over 700 MS patients and more than 5,000 control subjects. The research team was able to trace back to the time of initial EBV infection in some participants, and monitor the development of MS over time. Consistently high antibody levels were linked to a significantly elevated risk of developing MS and rapid disease progression, according to findings published in Nature Communications. The researchers suggest that the test could be used for screening populations at increased risk for MS, such as those with a history of Infectious Mononucleosis. However, further studies are required before the test can be implemented in clinical practice.

"Our study shows that, when using this antibody assay, the development of MS becomes immunologically predictable long before the first symptoms appear," said study leader Elisabeth Puchhammer-Stöckl.


New
Gold Member
Cardiovascular Risk Test
Metabolic Syndrome Array I & II
POC Helicobacter Pylori Test Kit
Hepy Urease Test
New
HBV DNA Test
GENERIC HBV VIRAL LOAD VER 2.0
New
Silver Member
Rapid Test Reader
DIA5000
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Hematology

view channel
Image: New research points to protecting blood during radiation therapy (Photo courtesy of 123RF)

Pioneering Model Measures Radiation Exposure in Blood for Precise Cancer Treatments

Scientists have long focused on protecting organs near tumors during radiotherapy, but blood — a vital, circulating tissue — has largely been excluded from dose calculations. Each blood cell passing through... Read more

Immunology

view channel
Image: The test could streamline clinical decision-making by identifying ideal candidates for immunotherapy upfront (Xiao, Y. et al. Cancer Biology & Medicine July 2025, 20250038)

Blood Test Predicts Immunotherapy Efficacy in Triple-Negative Breast Cancer

Triple-negative breast cancer (TNBC) is an aggressive subtype lacking targeted therapies, making immunotherapy a promising yet unpredictable option. Current biomarkers such as PD-L1 expression or tumor... Read more

Microbiology

view channel
Image: New diagnostics could predict a woman’s risk of a common sexually transmitted infection (Photo courtesy of 123RF)

New Markers Could Predict Risk of Severe Chlamydia Infection

Chlamydia trachomatis is a common sexually transmitted infection that can cause pelvic inflammatory disease, infertility, and other reproductive complications when it spreads to the upper genital tract.... Read more

Technology

view channel
Image: The sensor can help diagnose diabetes and prediabetes on-site in a few minutes using just a breath sample (Photo courtesy of Larry Cheng/Penn State)

Graphene-Based Sensor Uses Breath Sample to Identify Diabetes and Prediabetes in Minutes

About 37 million U.S. adults live with diabetes, and one in five is unaware of their condition. Diagnosing diabetes often requires blood draws or lab visits, which are costly and inconvenient.... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.